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Abstract
Statins are important lipid-lowering agents with other pleiotropic effects. Several studies
have explored a possible protective effect of statins to reduce the morbidity and mortality of
many infectious diseases. Staphylococcus aureus is one of the main pathogens implicated
in nosocomial infections; its ability to form biofilms makes treatment difficult. The present
study observed the MIC of atorvastatin, pravastatin and simvastatin against S. aureus,
Pseudomonas aeruginosa, Escherichia coli and Enterococcus faecalis. Simvastatin was
the only agent with activity against clinical isolates and reference strains of methicilin-sensi-
tive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). Thus, the effects of sim-
vastatin on the growth, viability and biofilm formation of S. aureus were tested. In addition, a
possible synergistic effect between simvastatin and vancomycin was evaluated. Simvastat-
in’s MIC was 15.65 µg/mL for S. aureus 29213 and 31.25 µg/mL for the other strains of S.
aureus. The effect of simvastatin was bactericidal at 4xMIC and bacteriostatic at the MIC
concentration. No synergistic effect was found between simvastatin and vancomycin. How-
ever, the results obtained against S. aureus biofilms showed that, in addition to inhibiting ad-
hesion and biofilm formation at concentrations from 1/16xMIC to 4xMIC, simvastatin was
also able to act against mature biofilms, reducing cell viability and extra-polysaccharide pro-
duction. In conclusion, simvastatin showed pronounced antimicrobial activity against S. au-
reus biofilms, reducing their formation and viability.
Introduction
Simvastatin is a lipophilic drug that belongs to the group of statins. The statins are lipid-lower-
ing agents that are involved in the reduction of cardiovascular morbidity and mortality [1].
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These drugs exhibit a good margin of safety and tolerability with a low frequency of side effects
and are the most commonly used agents for the reduction of lipids in patients with elevated
cholesterol levels [2, 3]. All statins act by the same mechanism of action, competitively inhibit-
ing the enzyme 3-hydroxy-3-methyl-glutaryl-CoenzymeA reductase (HMG-CoA) and causing
a decrease in the biosynthesis of cholesterol and increased removal of circulating low-density li-
poprotein (LDL) [4, 5].
Statins have effects other than lipid reduction, called pleiotropic effects, such as anti-inflam-
matory and immunomodulatory activities [6–8]. Many studies have evaluated the effect of stat-
ins on the prevention, morbidity and mortality of various infectious diseases. Some of these
studies have shown that statins can prevent the establishment of infections or even reduce mor-
tality rates in patients routinely taking statins. In patients with bacteremia and sepsis, the use of
statins was associated with lower mortality in recent studies [9–13]. However, other studies did
not find the same protective effect [14, 15]. Interestingly, some studies have demonstrated an
antimicrobial potential for statins against different bacterial species [16–20]. For example, sim-
vastatin was able to inhibit host-cell invasion [17] and Staphylococcus aureus growth [19, 21,
22]. In addition, atorvastatin, simvastatin and rosuvastatin showed activity against several ref-
erence bacteria and clinical isolates [19, 22].
Pseudomonas aeruginosa, Staphylococcus epidermidis, Enterobacter spp, Escherichia coli,
Klebsiella spp, Acinetobacter spp and especially Staphylococcus aureus are frequently involved
in nosocomial infections [23]. S. aureus, one of the most important etiological agents of both
nosocomial and community-onset infections, produces several virulence factors, such as tox-
ins, adhesins and components of immune evasion [24]. These characteristics along with the
ability to form biofilms results in an increased capability of surviving in a hostile environment
[25]. The cells attached to the biofilm produce an extracellular matrix composed of polysaccha-
rides, proteins and DNA [26]. This matrix allows the bacterial cell to protect itself against the
host defense system and antimicrobial agents, which makes the treatment of nosocomial infec-
tions difficult [26].
In the present study, the activity of simvastatin, atorvastatin and pravastatin was evaluated
against a range of clinically important pathogens through susceptibility methods. A possible
synergistic action of vancomycin and simvastatin was also tested using a microtiter checker-
board method. Finally, the effects of simvastatin on S. aureus adhesion, biofilm viability and
polysaccharide and protein production were further evaluated.
Materials and Methods
Chemicals and Experimental Groups
Atorvastatin (atorvastatin calcium salt trihydrate), pravastatin (pravastatin sodium salt hy-
drate) and simvastatin (Sigma Chemical Co—St. Louis, MO, USA) were used for minimum in-
hibitory concentration (MIC) experiments. Atorvastatin and simvastatin were dissolved in
100% DMSO, and pravastatin was dissolved in distilled-deionized water. The final concentra-
tion of DMSO was 2.5%. Both gentamicin and vancomycin dissolved in deionized water were
used as antimicrobial standards.
Formulations were distributed into microtiter plate wells as follows: a) experimental groups
(culture medium + bacteria + statin or antimicrobial standard); b) positive control (culture me-
dium + bacteria); c) vehicle control (culture medium + bacteria + DMSO); d) negative control
(culture medium + statin or antimicrobial standard); e) medium negative control (culture me-
dium); f) negative vehicle control (culture medium + DMSO). All tests were performed with
six replicates on at least two separate occasions.
Simvastatin and S. aureus Biofilm
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Bacterial strains and Culture Conditions
The following reference strains were used: Staphylococcus aureus ATCC 29213 (methicilin-sen-
sitive S. aureus—MSSA), S. aureus ATCC 6538 (a standard for testing antimicrobial agents), S.
aureus ATCC 14458 (enterotoxin B gene present), S. aureus ATCC 33591 (methicillin-resistant
S. aureus—MRSA), methicillin-oxacillin-resistant S. aureus ATCC 43300 (MRSA; mecA gene
present), Pseudomonas aeruginosa ATCC 27853, P. aeruginosa ATCC 25619, Escherichia coli
ATCC 25922, E. coli ATCC 10536, Enterococcus faecalis ATCC 29212. S. aureus isolated from
clinical samples were also tested. MRSA isolated from sputum samples (strains HC 3817719,
HC 10106876, HC 9120358) and MSSA from blood cultures (strains HC 12092392 and HC
985444) were kindly provided by Professor Carlos Emilio Levy (Faculty of Medical Sciences,
Department of Clinical Pathology, State University of Campinas, Brazil). All bacteria were
stored in Tryptic Soy broth (TSB—Difco Co., Detroit, MI, USA) with 20% glycerol at -80°C.
Strains were routinely cultured on TSA plates, in aerobic conditions, at 35°C.
Mueller Hinton broth (MHB—Difco Co.) was used for MIC and planktonic tests. For bio-
film experiments, S. aureus ATCC 29213, HC 3817719 and HC 12092392 were cultivated in
Brain Heart Infusion (BHI—Difco Co., Detroit, MI, USA) with 1% D-glucose (Sigma Chemical
Co—Poole, UK). These strains were chosen because they displayed a better biofilm formation
profile in tests performed in our laboratory (data not shown).
For all of the following tests, the bacterial inoculum was prepared in 0.9% NaCl at an optical
density of 0.1 at 660 nm, which was equivalent to 1 to 2 x 108 CFU/mL. In each test, the
amount of the initial bacterial load was 5 x 105 CFU/mL.
Minimum Inhibitory Concentration (MIC)
The MIC was determined by the broth microdilution method as previously described by The
Clinical and Laboratory Standards Institute [27]. Concentrations for all statins ranged from
250 to 0.24 μg/mL and from 100 to 0.06 μg/mL for antimicrobial standards. Two-fold dilutions
were obtained in 96-well plates with 100 μL of MHB per well. Then, the bacterial suspension
(100 μL) was inoculated, and the plates were incubated for 24 h at 35°C. The lowest concentra-
tion with any visible bacterial growth was taken as the MIC. In addition, bacterial growth was
assessed by optical density measurement (660 nm).
Time-kill assays
For all of the following assays, vancomycin and simvastatin (the statin with the best antimicro-
bial activity) were tested against S. aureus ATCC 29213.
The time-kill assay was adapted from a previously described method [28, 29]. MIC and
4xMIC concentrations were chosen according to the data obtained from the previous experi-
ments. The time-kill assay was performed as described in the MIC assay, and 25-μL samples
were taken from the microtiter plates after 0, 2, 4, 8 and 12 h of incubation and spread on TSA
plates. Viable colonies were counted after 24 h incubation. Killing curves were constructed by
plotting the log10 CFU/mL versus time over 12 h.
Post-antibiotic effect (PAE)
Determination of the PAE was adapted from previously described methods [28, 30]. Concen-
trations were four times higher than the MIC (4xMIC), two times higher than the MIC
(2xMIC), the MIC and one-half the MIC (½xMIC). Twenty-four-well plates containing the
testing substances were incubated for 2 h. Samples were centrifuged for 5 minutes at 1400 g,
Simvastatin and S. aureus Biofilm
PLOS ONE | DOI:10.1371/journal.pone.0128098 May 28, 2015 3 / 17
the supernatant was removed, and new fresh medium was added. This procedure was repeated
two times to ensure complete removal of drugs.
The pellet was suspended in culture medium, diluted 1:10 in tubes containing a final volume
of 5 mL of culture medium and incubated at 35°C. Samples of 25 μL were collected before and
after washing every hour until there was visible growth (OD660nm = 0.3) and plated on TSA
plates to obtain viable counts. The PAE was calculated using the following equation: PAE = T
—C, where T is the time required for the initial bacterial culture to increase by 1 log10 CFU/mL
from the removal of the antimicrobial, and C represents the time required for bacterial cultures
not treated with an antimicrobial to increase 1 log10 CFU/mL.
Checkerboard Microdilution Assay
To evaluate a possible interaction between simvastatin and vancomycin, a checkerboard micro-
dilution assay was used [31, 32]. Simvastatin and vancomycin were prepared at four times of
the final concentration in separated plates. Then, 50 μL simvastatin and 50 μL of vancomycin
were mixed and transferred to a new plate. Finally, 100 μL of bacterial suspension was inoculat-
ed, and the plates were incubated. Analyses of results were based on the value of the FICI (frac-
tional inhibitory concentration index) that was calculated using the following formula:
X
FICI ¼ FICIA þ FICIB ¼ MICAB =MICA þ MICBA =MICB
where MICA and MICB are the MICs of drugs A and B when acting alone and MICAB and
MICBA are the MICs of drugs A and B when acting in combination, respectively.
FICI values< 0.5 represent synergism in the interaction between drugs. FICI values be-
tween 0.5< FICI< 4.0 are classified as indifferent, and FICI values> 4.0 are classified
as antagonism.
Biofilm formation assay
For this assay, vancomycin and simvastatin were tested against S. aureus ATCC 29213, MRSA
(HC 3817719) and MSSA (HC 12092392).Biofilm formation experiments were conducted
using U-bottom, 96-well plates. Concentrations of simvastatin and vancomycin ranged from
1/28xMIC to 4xMIC. Two-fold dilutions were obtained in 96-well plates with 100 μL of BHI
with 1% glucose per well. Then, the bacterial suspension (100 μl) was inoculated, and the plates
were incubated for 24 h at 35°C.
After 24 h of incubation, the plates were washed with distilled-deionized water to remove
dead or unattached cells. After drying at room temperature, the quantification of biofilm
formed in each well was made by optical density measurement (OD575nm) after the addition of
0.4% crystal violet solution and 100% ethanol [33].
Analysis of biofilm formation by scanning electron microscopy (SEM)
The effect of simvastatin on biofilm formation was analyzed by SEM. The biofilm was formed
as described in the previous section with the following modifications. After growing for 24 h in
Lab-Tek Chambers (Nunc, Naperville, IL, USA), 3% glutaraldehyde/PBS (v / v, pH 7.4) was
added for 12 h. Next, the samples were dehydrated with ethanol (50% to 100%). The biofilms
were coated with gold and examined using a JEOL JSM5600LV (JEOL Ltd., Tokyo, Japan)
scanning electron microscope [34].
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Biofilm viability assay
To assess the effect of simvastatin on the viability of mature biofilms, 24-h biofilms were ex-
posed to the antimicrobial drugs. Biofilms of S. aureus ATCC 29213 were formed in cellulose
acetate membranes filters (diameter: 25 mm; pore size: 0.2 μm; Sartorius AG, Germany) placed
at the bottom of 6-well plates.
After biofilm formation, membranes were transferred to a new plate containing culture
media and the antimicrobial substances at 4xMIC. The plates were then incubated for 24 h at
35°C. Membranes were removed from the plates and washed three times with 5 mL of 0.9%
NaCl for 5 s each. Then, membranes were transferred to polystyrene tubes containing 5 mL of
0.9% NaCl and sonicated (Vibra Cell 400W, Sonics & Materials Inc., Newtown, CT, USA) in
the 5% range and 20 W for 30 seconds for dispersion of the biofilm. Samples of 10 μL were col-
lected, plated on TSA and kept at 35°C for 24 h. After this period, viable counts
were performed.
Quantification of polysaccharides, proteins and biomass
In addition to viability of the biofilm, the production of polysaccharides, proteins and biomass
(dry weight) after exposure to simvastatin were also analyzed.
The biofilms were formed and sonicated as described in the biofilm viability assayA portion
(800 μL) of the biofilm suspension was collected, and the extraction of insoluble extracellular
polysaccharides was performed with 1 M NaOH as described by Aires et al. [35]. After this
step, biofilms were boiled at 100°C for 15 minutes for cell disruption, allowing extraction of in-
tracellular polysaccharides with 1 M NaOH [35]. Quantification was performed using the phe-
nol-sulfuric method [36]. Protein extraction was conducted using a 2 M NaOH solution [37]
and subsequently quantified by colorimetric assays through BCA protein quantification
(Thermo Scientific, Scottsdale, AZ, USA). For biomass quantification (dry weight), 1000 μL of
each sample was centrifuged, and the pellet was dried in a lyophilizer (Lyo Chamber Guard
Christ LCG 121505 PMMA (Nova Analítica) Alpha 2–4 LD plus) and then weighed.
Statistics
All tests were performed using six replicates per group on at least two separate occasions. Data
were analyzed by using GraphPad version 5.00 (San Diego, CA, USA). Data distribution was
tested using the Shapiro-Wilks test. Data showing a normal distribution were compared using
an ANOVA, and differences between control and treatment groups were determined using the
Bonferroni post-hoc test. Non-normally distributed data were analyzed by Kruskal-Wallis and
Dunn post-hoc tests. The significance level was set at 5%.
Results
Only simvastatin has antibacterial activity against S. aureus
Simvastatin showed activity against all strains of S. aureus, but had no effect against the other
species tested. The MIC values for simvastatin and the antimicrobial standards are shown in
Table 1. No MIC for atorvastatin and pravastatin were found at the concentrations tested. The
concentrations of DMSO (2.5% V/V) used in all tests did not interfere with bacterial growth. P.
aeruginosa 27853 and 25619, E. coli 25922 and 10536 were resistant to vancomycin, but only S.
aureus 43300 was resistant to gentamicin. All MIC values for the antibiotics were in accordance
with CLSI.
The effect of statins on S. aureus strains is dose and drug dependent, as observed in Fig 1.
Pravastatin also caused a reduction in the growth of S. aureus strains, but it did not completely
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inhibit those strains. Simvastatin effects against S. aureus were more prominent, even with sub-
MIC concentrations (p< 0.05, ANOVA-Bonferroni).
Fig 2 shows the effect of simvastatin on S. aureus cell viability during 12 h of exposure. Sim-
vastatin at a concentration of 4xMIC exhibited a bactericidal effect against S. aureus ATCC
29213 and caused a significant reduction in the number of viable cells (Fig 2A), but the MIC
concentration showed a bacteriostatic effect (Fig 2B) because the number of cells remained
constant during 12 h of exposure to this substance. Vancomycin showed a bactericidal effect
for both concentrations tested. However, more time was required to kill 100% of cells at the
MIC.
Fig 2C shows the post-antibiotic effect (PAE) for both drugs. Vancomycin showed a greater
PAE than simvastatin; however, no differences (p> 0.05) between the PAEs of the two drugs
were observed at 4xMIC. DMSO did not have any effect in either time-kill or PAE assays.
Simvastatin has no synergistic effect with Vancomycin
A combination of simvastatin and vancomycin was tested to evaluate if there was any interac-
tion between the two antimicrobials. FICI values lower than 0.5 represent synergism, values be-
tween 0.5 and 4.0 are classified as indifferent and FICI values higher than 4.0 are classified as
antagonism. In the checkerboard test, FICI values found were higher than 0.5 as shown in
Table 2, indicating that there is no synergistic or antagonist effect between simvastatin and
vancomycin against S. aureus.
Simvastatin inhibits biofilm formation of S. aureus
Fig 3A shows the optical densities for simvastatin and vancomycin cultures representing the ef-
fects of these substances on biofilm formation by S. aureus. Substances were added at the begin-
ning of the biofilm formation assay. The concentrations tested ranged from 1/128xMIC to
4xMIC, and thus, the concentrations for each drug were: 0.12–62.6 μg/mL for simvastatin and
0.012–6.24 μg/mL for vancomycin.
Simvastatin in concentrations from 1/16xMIC up to 4xMIC (from 0.98 to 62.6 μg/mL) sig-
nificantly reduced S. aureus 29213 biofilm formation (p< 0.05, ANOVA- Bonferroni). A
Table 1. MIC (μg/mL) for simvastatin, gentamicin and vancomycin.
Bacterial strains Simvastatin Gentamicin Vancomycin
S. aureus 29213 15.65 0.78 1.56
S. aureus 33591 31.25 3.12 1.56
S. aureus 14458 31.25 0.78 1.56
S. aureus 43300 31.25 —— 1.56
S. aureus 6538 31.25 1.56 1.56
S. aureus HC 3817719 31.25 0.78 1.56
S. aureus HC 10106876 31.25 1.56 1.56
S. aureus HC 9120358 31.25 1.56 3.12
S. aureus HC 12092392 31.25 0.78 1.56
S. aureus HC 985444 31.25 0.78 1.56
P. aeruginosa 27853 —— 0.78 ——
P. aeruginosa 25619 —— 0.39 ——
E. coli 25922 —— 1.56 ——
E. coli 10536 —— 0.78 ——
E. faecalis 29212 —— 6.25 3.12
doi:10.1371/journal.pone.0128098.t001
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Fig 1. Mean and standard deviation of optical density (660 nm) representing the bacterial growth of S. aureuswhen exposed to simvastatin and
pravastatin for 24 h. Significant differences between the treatment and the control group were considered when *p<0.05, **p<0.01 (ANOVA, Bonferroni).
doi:10.1371/journal.pone.0128098.g001
Simvastatin and S. aureus Biofilm
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significant inhibition of biofilms was also observed for the antimicrobial standard drug at con-
centrations higher than 1/2xMIC (from 0.78 to 6.24 μg/mL). When analyzed by MIC range,
simvastatin was able to reduce biofilm formation more significantly up to the 1/16xMIC con-
centration compared to vancomycin (p< 0.05, two-way ANOVA- Bonferroni). For S. aureus
29213, complete inhibition could be accomplished with simvastatin at 2x and 4xMIC, while
this could be accomplished with vancomycin at ½ MIC and MIC concentrations. The images
obtained by SEM confirmed the inhibitory effect of simvastatin on S. aureus 29213 biofilms,
showing a reduction in the number of cells and the extracellular matrix of the biofilm (Fig 3B).
Simvastatin was also able to reduce biofilm formation of clinical isolates in concentrations
from 1/32xMIC up to 4xMIC, while vancomycin reduced bacterial adhesion at concentrations
higher than 1/16xMIC for MSSA and 1/2xMIC for MRSA (Fig 4). DMSO did not alter S. aure-
us biofilm formation (p> 0.05).
Fig 2. A. Effect of simvastatin and vancomycin on cell viability during 12 h exposure, concentration equivalent to 4xMIC. B. Effect of simvastatin and
vancomycin on cell viability during 12 h exposure, concentration equivalent to MIC. Comparisons were made among the different times of exposure and the
time 0, before exposure to the substances (control). C. Post-antibiotic effect (PAE) of simvastatin and vancomycin. PAE were compared at each
concentration between the substances. (*p<0.05; ANOVA-Bonferroni).
doi:10.1371/journal.pone.0128098.g002
Table 2. FICI values for association between simvastatin and vancomycin.
Bacterial strain FICI
S. aureus 29213 0.56
S. aureus 33591 1.06
S. aureus 14458 1.00
S. aureus 43300 1.06
S. aureus 6538 1.03
doi:10.1371/journal.pone.0128098.t002
Simvastatin and S. aureus Biofilm
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Simvastatin decreases cell viability and alters the production of
polysaccharides in mature biofilms
In these experiments, after 24 hours of biofilm growth (mature biofilm), S. aureus biofilms
were exposed to simvastatin and vancomycin and viability, polysaccharide and protein produc-
tion were evaluated. The cell viability of S. aureus 29213 biofilms after treatment with simva-
statin and vancomycin is shown in Fig 5.
The results showed that simvastatin at4xMIC (62.5 μg/mL) was able to significantly reduce
viable cells in biofilm when compared to the control and vehicle groups (p<0.005, Kruskal-
Wallis, Dunn), but vancomycin at 4xMIC (6.25 μg/mL) showed no difference when compared
to the control group (p> 0.05). In concentrations higher than 4xMIC (10xMIC = 15.6 μg/mL
and 40xMIC = 62.5 μg/mL), vancomycin also significantly reduced biofilm viability (p> 0.05).
The concentration of 62.5 μg/mL Simvastatin was as effective as 15.6 μg/mL vancomycin for
killing biofilm. Vancomycin at 62.5 μg/mL showed a more pronounced reduction than simva-
statin at 62.5 μg/mL and vancomycin at 15.6 μg/mL (p> 0.05), but did not produce a 100%
killing effect. Due to poor solubility, 4xMIC was chosen as the highest concentration tested for
simvastatin. DMSO did not reduce the number of viable cells. Thus, simvastatin was effective
in reducing bacterial viability of mature S. aureus 29213 biofilms in a comparable manner
to vancomycin.
As simvastatin inhibited S. aureus ATCC 29213 biofilms, it was hypothesized that this statin
could also interfere with the extracellular matrix of the biofilm. The results for insoluble
Fig 3. A. Mean and standard deviation of optical densities (575 nm) representing the biofilm formation of S. aureus 29213 in the presence of
simvastatin and vancomycin. Different letters represent significant differences; comparisons were made for each dilution, the control group and each
concentration of simvastatin and vancomycin. B. Images obtained by SEM showing biofilm formation of S. aureus 29213 in the presence of simvastatin. The
4xMIC, 2xMIC and MIC concentrations are in column 1 (top to bottom). The½xMIC concentration, vehicle group (DMSO) and control group are in column 2
(top to bottom). (p<0.05, two-way ANOVA, Bonferroni).
doi:10.1371/journal.pone.0128098.g003
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Fig 4. Mean and standard deviation of optical densities (575 nm) representing the biofilm formation of
MSSA (HC 12092392) and MRSA (HC 3817719) in the presence of simvastatin and vancomycin.
Different letters represent significant differences; comparisons were made for each dilution, the control group
and each concentration of simvastatin and vancomycin. (p<0.05, two-way ANOVA, Bonferroni).
doi:10.1371/journal.pone.0128098.g004
Simvastatin and S. aureus Biofilm
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extracellular polysaccharide (EPSI) and intracellular polysaccharide (IPS) are both shown in
Table 3. Simvastatin reduced the production of EPSI (p<0.05) and increased the production of
IPS when compared with control (p<0.05, Kruskal-Wallis, Dunn). The production of soluble
extracellular polysaccharide (EPS) was under the limit of detection. However, simvastatin did
not change total protein production (p>0.05; Kruskal-Wallis, Dunn). DMSO did not alter the
amount of polysaccharide, protein or biomass.
Discussion
The potential for the pleiotropic effects of statins has generated studies to investigate the role of
these drugs in the prevention, morbidity and mortality of different infections [10–15]. Their
antimicrobial activity was previously proposed and investigated [16–19, 21, 22]. We evaluated
the antimicrobial activity of atorvastatin, pravastatin and simvastatin against 15 bacterial
strains associated with nosocomial infections. In addition, as simvastatin showed activity
against S. aureus, we have explored its effects on S. aureus planktonic cells and biofilm.
In our study, simvastatin showed 100% inhibition only against S. aureus. In addition, sub-
MIC concentrations were able to reduce the growth of S. aureus even at concentrations lower
than the MIC. The MICs found in the present study were lower than the MICs shown previ-
ously in other studies of S. aureus [19] and other bacterial species [22]. However, the values
found for antimicrobial standards are in accordance with CLSI [27], demonstrating that the
Fig 5. Median and 5–95 percentiles of CFU/mL representing the cell viability of S. aureus 29213 biofilm
after exposure to simvastatin and vancomycin for 24 h. Significant differences between the treatment and
the control group when **p < 0.01 (Kruskal-Wallis—Dunn).
doi:10.1371/journal.pone.0128098.g005
Table 3. Effects of simvastatin on the production of polysaccharides, proteins and biomass of S. aureus biofilm.
EPSI (μg/mg) IPS (μg/mg) Proteins (μg/mg dry weight) Biomass (mg)
Simvastatin 22.7 ± 9.0* 78.6 ± 25.4* 2.3 ± 0.4 0.66 ± 0.12*
Control 40.7 ± 9.6 34.1 ± 8.6 1.9 ± 0.4 0.93 ± 0.13
EPSI- insoluble extracellular polysaccharide. IPS- intracellular polysaccharide. The values of polysaccharides and proteins were normalized by dry weight.
Significant differences between the treatment and the control group when:
*p < 0.05 (Kruskal-Wallis).
doi:10.1371/journal.pone.0128098.t003
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method used in our study was suitable. Finally, Bergman et al. [18] found a MIC value of
15.6 μg/mL for simvastatin against Streptococcus pneumoniae, which is a concentration that is
very close to the one found in the present study.
Atorvastatin and pravastatin did not present full inhibitory activity, as demonstrated by the
MIC tests. However, pravastatin significantly reduced the growth of S. aureus. In the present
study, it was also observed that simvastatin and pravastatin had a slightly inhibitory effect on
growth in E. coli, P. aeruginosa and E. faecalis (data not shown). Masadeh et al. [22] previously
reported inhibitory activity for simvastatin and atorvastatin against several species, including
E. coli, P. aeruginosa and E. faecalis. The enhanced antimicrobial activity of simvastatin in com-
parison to pravastatin and atorvastatin may be related to differences in their chemical charac-
teristics, as described previously [19, 22]. Pravastatin and simvastatin are semi-synthetic forms
that are derivatives of lovastatin, a metabolic product of Penicillium citrinum [38], and atorva-
statin is the pure synthetic form. Simvastatin and atorvastatin are lipophilic, but pravastatin
has hydrophilic properties [39]. Thus, simvastatin probably crosses the cell membrane more
easily, causing bacterial inhibition in a dose-dependent manner. Although lipophilic, atorva-
statin has no significant antimicrobial activity. This molecule is not derived from a fungal me-
tabolite, which may be the reason for lacking antimicrobial effects. However, further studies on
the structure-activity relationship should be conducted to better understand the antimicrobial
properties of statins.
To better understand the antimicrobial properties of statins, we investigated their effects on
S. aureus 29213 in planktonic and biofilm assays. We first evaluated cell viability when S. aure-
us 29213 was exposed to simvastatin for 2, 4, 8 and 12 h (time-kill assays). At 4xMIC, simva-
statin reduced the number of viable cells, especially after 12 h of exposure. However, at the
MIC, the number of viable cells remained constant during all periods of exposure. Vancomycin
showed a bactericidal effect at both concentrations and reduced the number of viable cells
more significantly than simvastatin. In addition, we also verified how long these effects persist
after removal of the drug, also known as the post-antibiotic effect (PAE). For the 4xMIC con-
centration, simvastatin and vancomycin showed a similar PAE. In this experiment, bacteria
was exposed to the antibiotics for a short period (2 h) and then transferred to a drug free medi-
um. Simvastatin and vancomycin showed a suppressive effect on S. aureus growth that per-
sisted after drug removal, in the “recovery period”. The ability of simvastatin to produce a PAE
similar to vancomycin is an interesting finding, as theoretically it could suppress bacterial
growth for a longer period of time, even when concentrations fall below the MIC [30]. PAE is
an important property that impacts on antimicrobial regimens, as substances that do not pres-
ent this effect require more frequent antimicrobial administration than those that present this
post-effect [30].
Previous studies have reported in vitro synergistic and antagonistic effects of the association
between statins and antifungals [40–42]. Therefore, we investigated a possible interaction be-
tween simvastatin and vancomycin using a checkerboard test. However, the combination of
these drugs had no synergistic effect against any strain of S. aureus. The FICI value found for S.
aureus 29213 was low compared to the other strains, but more studies are needed to verify if
this interaction has some potential.
Despite the importance of determining the MIC and antibacterial activity against planktonic
cells, microorganisms are not usually found in body liquids [43]. To face the adversities of the
environment, microorganisms adhere to surfaces and grow grouped together with extracellular
polymeric substances (EPS), forming communities known as biofilms [43, 44]. Biofilm forma-
tion involves four steps: (1) reversible adhesion to a surface, (2) production of EPS (irreversible
adhesion), (3) microcolony formation and intense production of EPS and (4) biofilm disper-
sion [44, 45].
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Our results show that simvastatin was able to inhibit biofilm formation in concentrations 16
times lower than MIC for S. aureus 29213 and 32 times lower than MIC for clinical isolates.
This inhibition was confirmed by images obtained by scanning electron microscopy (SEM).
Considering both vehicle and control groups, it was possible to observe a biofilm at a mature
stage with the cells immersed in an extracellular matrix. In the presence of simvastatin, howev-
er, few cells adhered to the surface with drug concentrations equal to or higher than the MIC.
For the ½xMIC concentration, more cells adhered, but the biofilm failed to develop and
achieve step 3. Thereby, simvastatin inhibits biofilm formation by S. aureus, probably prevent-
ing the adherence of cells at concentrations higher than the MIC and the development of bio-
films at sub-MIC concentrations.
The fight against mature biofilms has become a challenge. They are more resistant to anti-
microbial agents, which makes treatment difficult and leads to complications for the patient
[46]. We investigated the effect of simvastatin on S. aureus biofilms with 24 h of growth at a
more advanced stage of maturation. Simvastatin exhibited considerable activity at 4xMIC
(62.5 μg/mL), reducing cell viability with similar effects to vancomycin 10xMIC (15.6 μg/mL)
In terms of concentration in μg/mL, vancomycin showed killing effects in smaller concentra-
tions than simvastatin. However, when comparing both substances in terms of MIC range,
simvastatin showed better results. The concentration of antibiotic required to kill cells in bio-
films is much higher than to kill planktonic cells, sometimes 100 or 1000 times the MIC [26].
Therefore, our findings revealed a potential for simvastatin to be explored because in concen-
trations only 4 times the MIC it has the ability to decrease cell viability. Unfortunately, the diffi-
culty of diluting simvastatin did not allow testing at concentrations higher than 4xMIC for
biofilm tests
Several mechanisms explaining the resistance of biofilms have been described [26, 46]. The
extracellular matrix is implicated as an important mechanism, especially in decreasing the pen-
etration of an antibiotic [26]. We hypothesized that the effect of simvastatin could also involve
an effect on two important components of EPS, polysaccharides and proteins. The EPSI con-
tributes to structure and is responsible for the integrity of biofilms [43]. Some EPSI are also as-
sociated with resistance in bacterial biofilms. For example, poly-(1,6)-N-acetyl-D-glucosamine
(PNAG), the major extracellular polysaccharide in S. aureus, is responsible for preventing fluid
convection and the transport of solute through biofilms [47]. After treatment with simvastatin,
the biofilm showed a reduction in the production of EPSI and an increase in the production of
IPS when compared to the control group. The increase in production of IPS in some bacteria,
such as S.mutans, is associated with a nutrition reservoir allowing the extension of survival in
limiting conditions [48]. A possible hypothesis for this finding would be that in an attempt to
increase its survival in the presence of simvastatin, S. aureus decreases the production of EPSI
to produce reserve polysaccharides. This change could also explain the excellent effect of sim-
vastatin on S. aureus viability. Because EPSI is responsible for biofilm structure and is a major
component of the extracellular matrix, a reduction in its production could lead biofilms to be
more accessible to drugs. However, more studies are needed to understand the role of simva-
statin in the production of polysaccharides.
Simvastatin did not significantly alter the amount of protein. The production of proteins is
generally more intense during biofilm formation, because they play a key role in the coloniza-
tion of biofilms [44]. Thus, the absence of an effect on protein production is understandable.
Perhaps a qualitative study can better determine if simvastatin has some effect on the produc-
tion of proteins. The reduction in the biomass of biofilms is probably due to a reduction in
polysaccharides because they are the major fraction of the EPS [44].
The concentrations found to have antimicrobial properties are a thousand times higher
than the plasmatic concentrations achieved in patients undergoing statin therapy [18]. Thus,
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simvastatin doses have to be increased for clinical purposes, but safety in higher doses is un-
known. In addition, it is unknown if the antimicrobial concentrations found in the present
study would be achievable in plasma considering its poor solubility. However, regardless of
whether the physiological concentrations of simvastatin inhibit bacterial activity, our results
highlight an antimicrobial potential to be explored. Our study was the first to investigate the ef-
fect of simvastatin on bacterial biofilms, showing a substantial antimicrobial activity for this
statin. The identification and development of new antibiotics, especially those with new mecha-
nisms of action, are of utmost importance for public health worldwide [49]. As other antibiot-
ics, simvastatin would serve in future studies as a synthetic scaffold to originate new
antibiotics. For example, prontosil, a sulfa class of antibiotics was first developed as a dye and
nalidixic acid, was an intermediate in the synthesis of chloroquine (Fischbach1 and Walsh,
2009). We believe that studies of their molecular structure would introduce a new antibacterial
pharmacophore, which would be useful in the future as a template for the development of
new antibiotics.
In conclusion, simvastatin has antimicrobial activity against S. aureus biofilms, reducing
their formation, viability and polysaccharide production. These findings may contribute to the
search for new antibacterial drugs with consideration of the potential for simvastatin as an
antibiotic prototype.
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